Early-Stage trial halted: can new drug stop blood Cancer's comeback?
NCT ID NCT05065047
Summary
This early-phase study aimed to see if a drug called belantamab mafodotin (Blenrep) could help prevent multiple myeloma from returning in patients who had already relapsed and received a salvage stem cell transplant. Researchers wanted to test the safety of giving this drug as ongoing 'maintenance' therapy after the transplant procedure. The trial was terminated early and only enrolled 6 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.